NovImmune’s primary product development platform is based on several key strategic choices:

• Selection of medically relevant and fully validated targets.
• Choice of immune-related disorders, with unmet medical needs and large markets. The primary chronic indications will be inflammation and autoimmune diseases such as Rheumatoid Arthritis (RA), Type I Diabetes, Multiple Sclerosis, Crohn’s Disease and Psoriasis. For example, in the USA alone, there are more than 1 Million moderate to severe RA patients, 500’000 Crohn’s Disease patients, and more than 1 Million moderate to severe Psoriasis patients. Individual therapeutic MAbs developed for immune-related disorders often have multiple clinical indications, allowing multiple partnering and licensing opportunities.
• Fully human monoclonal antibodies are "best in class" therapeutic products with less immunogenicity.
• NovImmune has built in house operational excellence, for all the steps required, including sophisticated infrastructure, high throughput MAb screening and biological validation, focusing on immune-related disorders.
• Priority given to the development of NovImmune’s products from target selection through Phase II clinical trials. In parallel, NovImmune proposes to selected partners the possibility of co-development, offering a unique "one stop shop" covering under the same roof the entire pathway of MAb development.
• Fastest route to bringing drugs to the market.